AMICUS THERAPEUTICS INC (FOLD)       11.97  -0.21 (-1.72%)

11.97  -0.21 (-1.72%)

US03152W1099 - Common Stock - After market: 11.97 0 (0%)

AMICUS THERAPEUTICS INC11.97

NASDAQ:FOLD (12/8/2022, 4:20:00 PM)-0.21 (-1.72%)

After market: 11.97 0 (0%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 11-07 2022-11-07/bmo Earnings (Next) 02-22 2023-02-22
Ins Owners 0.98% Inst Owners 103.51%
Market Cap 3.36B Shares 280.94M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 80
IPO 05-31 2007-05-31

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

FOLD Daily chart

Company Profile

Amicus Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in Philadelphia, Pennsylvania and currently employs 496 full-time employees. The company went IPO on 2007-05-31. The firm's portfolio is Galafold (migalastat), which is the approved oral precision medicine for people living with Fabry disease. Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A (alpha-Gal A) enzyme in patients with genetic variants. Migalastat is approved under the trade name Galafold in the United States, European Union, United Kingdom and Japan. Its biologics program in its pipeline is Amicus Therapeutics GAA (AT-GAA), which is a clinical-stage treatment paradigm for Pompe disease. Pompe disease is a lysosomal disorder (LD) from deficiency in an enzyme, GAA. AT-GAA consists of a uniquely engineered rhGAA enzyme, ATB200, or cipaglucosidase alfa, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with AT2221 (miglustat) that functions as an enzyme stabilizer.

Company Info

AMICUS THERAPEUTICS INC

3675 Market Street

PHILADELPHIA PENNSYLVANIA 19104

P: 12159217600.0

CEO: John F. Crowley

Employees: 496

Website: https://www.amicusrx.com/

FOLD News

News Image17 days ago - Market News VideoInteresting FOLD Put And Call Options For July 2023News Image24 days ago - Amicus Therapeutics, Inc.Amicus Therapeutics to Present at the Stifel 2022 Healthcare Conference

PHILADELPHIA, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at...

News Image24 days ago - Amicus Therapeutics, Inc.Amicus Therapeutics to Present at the Stifel 2022 Healthcare ConferenceNews Image24 days ago - Pomerantz LLPSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amicus Therapeutics, Inc. - FOLD

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Amicus Therapeutics, Inc. ("Amicus" or the "Company") (NASDAQ: FOLD). Such...

News Imagea month ago - Amicus Therapeutics, Inc.Amicus Therapeutics Provides EU Regulatory Update for AT-GAA

PHILADELPHIA, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on...

News Imagea month ago - Amicus Therapeutics, Inc.Amicus Therapeutics Provides EU Regulatory Update for AT-GAA

FOLD Twits

Here you can normally see the latest stock twits on FOLD, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example